Anoro Ellipta Now Available for COPD

Anoro Ellipta Now Available for COPD
Anoro Ellipta Now Available for COPD

GlaxoSmithKline and Theravance announced that Anoro Ellipta (umeclidinium and vilanterol inhalation powder) is now available for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

RELATED: New Drug Product – ANORO ELLIPTA

Anoro Ellipta combines umeclidinium 62.5mcg, a long-acting muscarinic antagonist, and vilanterol 25mcg, a long-acting beta2-agonist (LABA). Umeclidinium exerts its effect through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. Vilanterol has shown the functional selectivity similar to salmeterol, another long-acting beta2-agonist. Anoro Ellipta is the first once-daily inhaler that combines two long-acting bronchodilators.

Anoro Ellipta is available as a 62.5mcg/25mcg strength inhaler containing 2 double-foil blister strips with 7- or 30-blisters each.

For more information call (888) 825-5249 or visit GSK.com.

Loading links....